Current treatment options for myeloma

Bibliography

• THE INTERNATIONAL MYELOMA WORKING GROUP: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol (2003) 121(5):749–757.
   PubMed Web of Science ®Google Scholar
• BLADE J, VESOLE DH, GERTZ M: High-dose therapy in multiple myeloma. Blood (2003) 102(10):3469–3470.
   PubMedGoogle Scholar
• •A detailed review of the role of high-dose treatment in MM.
   Google Scholar
• HEY, -WHEATLEY K, CLARK O, GLASMACHER A, ROSS H, DJULBEGOVIC B: Early versus deferredtreatment for early stage multiple myeloma. Cochrane Database Syst. Rev. (2003) 1:CD004023.
   Google Scholar
• WEBER DM, DIMOPOULOS MA, MOULOPOULOS LA et al.: Prognostic features of asymptomatic multiple myeloma. Br. J. HaematoL (1997) 97(4):810–814.
   PubMedGoogle Scholar
• MARIETTE X, ZAGDANSKI AM, GUERMAZI A et al.: Prognostic value of vertebral lesions detected by magnetic resonance imaging in patients with stage I multiple myeloma. Br. J. HaematoL (1999) 104(4):723–729.
   PubMedGoogle Scholar
• ••The value of MRI in stage I myelomapatients.
   Google Scholar
• ALEXANIAN R, HAUT A, KHAN AU et al.: Treatment of multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA (1969) 208(9):1680–1685.
   Google Scholar
• BELCH A. SHELLEY W, BERGSAGEL D et al.: A randomised trial of maintenance vs. no maintenance melphalan and prednisolone in responding multiple myeloma patients. Br. J. Cancer. (1988) 57(1):94–99.
   Google Scholar
• CROWLEY J, JACOBSON J, ALEXANIAN R: Standard-dose therapy for multiple myeloma: the Southwest Oncology Group experience. Semin. HematoL (2001) 38(3):203–208.
   PubMedGoogle Scholar
• ALEXANIAN R, DIMOPOULOS M: The treatment of multiple myeloma. N EngL J. Med. (1994) 330(7):484–489.
   PubMedGoogle Scholar
• DIMOPOULOS MA, POULI A. ZERVAS K et al.: Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann. Oncol. (2003) 14(7):1039–1044.
   Google Scholar
• •A comparison between VAD bolus chemotherapy and VAD with liposomal doxorubicin.
   Google Scholar
• RAJE N, POWLES R, KULKARNI Set al.: A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma. Br. J. HaematoL (1997) 97(1):153–160.
   Google Scholar
• AITCHISON RG, REILLY IA, MORGAN G, RUSSELL NH: Vincristine, adriamycin and high dose steroids in myeloma complicated by renal failure. Br. J. Cancer (1990) 61(5):765–766.
   PubMedGoogle Scholar
• ALEXANIAN R, DIMOPOULOS MA, DELASALLE K, BARLOGIE B: Primary dexamethasone treatment of multiple myeloma. Blood (1992) 80(4):887–890.
   PubMed Web of Science ®Google Scholar
• COOK G, SHARP RA, TANSEY P, FRANKLIN IM: A Phase I/II trial of Z-Dex (oral idarubicin and dexamethasone), an oral equivalent of VAD, as initial therapy at diagnosis or progression in multiple myeloma. Br. J. HaematoL (1996) 93(4):931–934.
   PubMedGoogle Scholar
• MACLENNAN IC, CHAPMAN C, DUNN J, KELLY K: Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet (1992) 339(8787):200–205.
   Google Scholar
• MYELOMA TRIALISTS' COLLABORATIVE GROUP: Combination chemotherapy vs. melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. J. Clin. OncoL (1998) 16(12):3832–3842.
   Google Scholar
• •A meta-analysis that compares combination chemotherapy and 'classical' MP treatment.
   Google Scholar
• FRITZ E, LUDWIG H: Interferon-alphatreatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann. OncoL (2000) 11(1 00:1427–1436.
   Google Scholar
• THE MYELOMA TRIALISTS' COLLABORATIVE GROUP: Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br. J. HaematoL (2001) 113(4):1020–1034.
   PubMedGoogle Scholar
• •A meta-analysis for the role of IFN in myeloma.
   Google Scholar
• WISLOFF F, HJORTH M, KAASA S, WESTIN J: Effect of interferon on the health-related quality of life of multiple myeloma patients: results of a Nordic randomized trial comparing melphalan-prednisone to melphalan-prednisone + alpha-interferon. The Nordic Myeloma Study Group. Br. J. HaematoL (1996) 94(2):324–332.
   PubMedGoogle Scholar
• WISLOFF F, GULBRANDSEN N: Health-related quality of life and patients' perceptions in interferon-treated multiple myeloma patients. Nordic Myeloma Study Group. Acta OncoL (2000) 39(7):809–813.
   Google Scholar
• CROWLEY J, FONSECA R, GREIPP P, MCCOY J, BARLOGIE B: Comparable survival in newly diagnosed multiple myeloma (MM) after VAD induction with high dose therapy using melphalan 140mg/ m2 + TBI 12 Gy (MEL + TBI) versus standard therapy with VBMCP and no benefit from interferon (IFN) maintenance: final clinical results of Intergroup trial S9321 in the context of IFM90 and MRC VII trials. Blood (2004) 104(11):156a-157a (Abstract).
   Google Scholar
• ATTAL M, HAROUSSEAU JL, STOPPA AM et aL: A prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl. J. Med. (1996) 335(2):91–97.
   PubMed Web of Science ®Google Scholar
• ••A randomised comparison between high-dose treatment with autologous stem cell support and standard chemotherapy in myeloma patients.
   Google Scholar
• CHILD JA, MORGAN GJ, DAVIES FE et al.: High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl. J. Med. (2003) 348(19):1875–1883.
   PubMed Web of Science ®Google Scholar
• ••A randomised comparison between high-dose treatment with autologous stem cell support and standard chemotherapy in myeloma patients.
   Google Scholar
• PALUMBO A, BRINGHEN S, PETRUCCI MT et al.: Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood (2004) 104(10):3052–3057.
   PubMedGoogle Scholar
• •The role of intermediate-dose melphalan in the management of patients with MM aged 50–70 years.
   Google Scholar
• FERMAND JP, RAVAUD P, KATSAHIAN S et al.: High dose therapy and autologous blood stem cell transplantation versus conventional treatment in multiple myeloma: results of a randomized trial in 190 patients 55 to 65 years of age. Blood (1999) 94\(Suppl. 1):396a (Abstract).
   Google Scholar
• BLADE J, SUREDA A, RIBERA JM et al.: High-dose therapy/ autotransplantation/ intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy. Definitive results from Pethema after a median follow-up of 66 months. Blood (2003) 102(11):42a (Abstract).
   Google Scholar
• MOREAU P, FACON T, ATTAL M et al.: Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intregroupe Francophone du Myelome 9502 randomized trial. Blood (2002) 99(3):731–735.
   PubMed Web of Science ®Google Scholar
• ••A randomised trial comparing twoconditioning regimen for autologous stem cell transplantation in MM.
   Google Scholar
• FERMAND JP, RAVAUD P, CHEVRET S et al.: High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomised clinical trial. Blood (1998) 92(9):3131–3136.
   PubMed Web of Science ®Google Scholar
• TERPOS E, APPERLEY JF, SAMSON D et al.: Autologous stem cell transplantation in multiple myeloma: improved survival in non-secretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplant (2003) 31(3):163–170.
   Google Scholar
• STEWART AK, VESCIO R, SCHILLER G et al.: Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: results of a multicenter randomized controlled trial. J. Clin. OncoL (2001) 19(17):3771–3779.
   PubMed Web of Science ®Google Scholar
• ALEGRE A, DIAZ-MEDIAVILLA J, SAN-MIGUEL J et al.: Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM and PETHEMA. Bone Marrow Transplant (1998) 21(2):133–140.
   PubMedGoogle Scholar
• MAJOLINO I, VIGNETTI M, MELONI G et al.: Autologous transplantation in multiple myeloma: a GITMO retrospective analysis on 290 patients. Haematologica (1999) 84(9):844–852.
   PubMedGoogle Scholar
• BARLOGIE B, SHAUGHNESSY J, TRICOT G et al.: Treatment of multiple myeloma. Blood (2004) 103(1):20–32.
   PubMed Web of Science ®Google Scholar
• ••A comprehensive review for the treatmentof patients with MM.
   Google Scholar
• FASSAS AB, SPENCER T, SAWYER J et al.: Both hypodiploidy and deletion of chromosome 13 independently confer poor prognosis in multiple myeloma. Br. J. HaematoL (2002) 118(4):1041–1047.
   PubMed Web of Science ®Google Scholar
• •The role of hypodiploidy and deletion of chromosome 13 in prognosis of patients with MM.
   Google Scholar
• SHAUGHNESSY J, JACOBSON J, SAWYER J et al.: Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy ensure long term survival in myeloma treated with total therapy I: interpretation in the context of global gene expression. Blood (2003) 101(10):3849–3856.
   PubMedGoogle Scholar
• ••The role of cytogenetics in the survival ofpatients who received total therapy I (a scheme introduced by Arkansas group).
   Google Scholar
• JACOBSON J, BARLOGIE B, SHAUGHNESSY J et al.: MDS-type abnormalities with myeloma signature karyotype: only 13% 1-year survival despite tandem transplants. Br. J. HaematoL (2003) 122(3):430–440.
   PubMedGoogle Scholar
• FACON T, AVET-LOISEAU H, GUILLERM G et al.: Chromosome 13 abnormalities identified by FISH analysis and serum 132-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood (2001) 97(6):1566–1571.
   PubMedGoogle Scholar
• ••The role of the combination ofchromosome 13 abnormalities and 132-microglobulin in survival of myeloma patients who received high-dose therapy.
   Google Scholar
• SHAUGHNESSY J, TIAN E, SAWYER J et al.: Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br. J. HaematoL (2003) 120(1):44–52.
   PubMedGoogle Scholar
• PORRATA LF, GERTZ MA, GEYER SM et al.: The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia (2004) 18(6):1085–1092.
   PubMedGoogle Scholar
• POLITOU M, TERPOS E, CRAWLEY D et al.: Pre-transplant VEGF levels in multiple myeloma are predictive for progression free survival. HematoL j (2004) 5\(Suppl. 2):513 (Abstract).
   Google Scholar
• HAROUSSEAU JL, SHAUGHNESSY J Jr, RICHARDSON P: Multiple myeloma. Hematology (2004):237–256.
   PubMedGoogle Scholar
• ATTAL M, HAROUSSEAU JL, FACON T et al.: Single versus double autologous stem cell transplantation for multiple myeloma. N. EngL J. Med. (2003) 349(20:2495–2502.
   PubMedGoogle Scholar
• ••A randomised comparison between singleand double autologous transplantation.
   Google Scholar
• CAVO M, CELLINI C, ZAMAGNI E et al.: Superiority of double over single autologous stem cell transplantation as first-line therapy for multiple myeloma. Blood (2004) 104(11):155a-156a (Abstract).
   Google Scholar
• SONNEVELD P, VAN DER HOLT B, SEGEREN C et al.: Intensive versus double intensive therapy in untreated multiple myeloma: updated analysis of the randomized phase III study Hovon 24 MM. Blood (2004) 104(11):271a-272a (Abstract).
   Google Scholar
• FERMAND JP, ALBERTI C, MAROLLEAU JP: Single versus double high dose therapy supported with autologous blood stem cell transplantation using unselected or CD34 enriched ABSC: results of a two by two designed randomized trial in 230 young patients with multiple myeloma. HematoL J. (2003) 4\(Suppl. 1):559 (Abstract).
   Google Scholar
• MORRIS C, IACOBELLI S, BRAND R et al.: Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. Clin. OncoL (2004) 22(9):1674–1681.
   Google Scholar
• •A retrospective analysis of the EBMT registry for the role of double autologous transplantation in patients with MM.
   Google Scholar
• LEE CK, BARLOGIE B, FASSAS A et al.: Third autotransplant for the management of 98 patients among 1358 who had received prior tandem autotransplants: benefit apparent when 2nd to 3r1 transplant interval exceeds 3 years. Blood (2004) 104(11):157a (Abstract).
   Google Scholar
• REECE DE, BREDESON C, PEREZ WS et al.: Autologous stem cell transplantation in multiple myeloma patients 60 vs. 6() years of age. Bone Marrow Transplant. (2003) 32(12):1135–1143.
   Google Scholar
• PALUMBO A. BRINGHEN S, PETRUCCI MT et al.: Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood (2004) 104(10):3052–3057.
   Google Scholar
• BADROS A, BARLOGIE B, SIEGEL E et al.: Results of autologous stern cell transplant in multiple myeloma patients with renal failure. Br. J. HaematoL (2001) 114(4):822–829.
   PubMed Web of Science ®Google Scholar
• •The role of autologous transplantation in patients with MM and renal failure.
   Google Scholar
• LEE CK, ZANGARI M, BARLOGIE B et al.: Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant. (2004) 33(8):823–828.
   PubMedGoogle Scholar
• SAN MIGUEL JF, LAHUERTA JJ, GARCIA-SANZ R et al.: Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J. (2000) 1(1):28–36.
   Google Scholar
• LOKHORST HM, WU K, VERDONCK LF et al: The occurrence of graft-versus host disease is the major predictive factor for response to donor lymphocyte infusions in multiple myeloma. Blood (2004) 103(11):4362–4364.
   PubMed Web of Science ®Google Scholar
• •The role of GVHD in predicting survival after DLI in MM.
   Google Scholar
• GAHRTON G, SVENSSON H, CAVO M et al.: Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br. J. HaematoL (2001) 113(1):209–216.
   PubMed Web of Science ®Google Scholar
• •The progress in allogeneic transplantation for myeloma between 1983–1993 and 1994–1998; a study performed by the EBMT registry.
   Google Scholar
• BJORKSTRAND B, LJUNGMAN P, SVENSSON H et al.: Allogenic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood (1996) 88(12):4711–4718.
   PubMed Web of Science ®Google Scholar
• ••A comparison between allogeneic andautologous transplantation for myeloma.
   Google Scholar
• ALYEA E, WELLER E, SCHLOSSMAN R et al.: Outcome after autologous and allogeneic stem cell transplantation for patients with multiple myeloma: impact of graft-versus-myeloma effect. Bone Marrow Transplant. (2003) 32(12):1145–1151.
   PubMedGoogle Scholar
• THE UK MYELOMA FORUM GUIDELINES WORKING GROUP: Guidelines on the diagnosis and management of multiple myeloma. Br. J. HaematoL (2001) 115(3):522–540.
   PubMedGoogle Scholar
• CORRADINI P, VOENA C, TARELLA C et al.: Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J. Clin. Oncol (1999) 17(1):208–215.
   PubMed Web of Science ®Google Scholar
• DURIE BG, KYLE RA, BELCH A et al.: Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. HaematoL j (2003) 4(6):379–398.
   Google Scholar
• LE BLANC R, MONTMINY-METIVIER S, BELANGER R et al.: Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant. (2001) 28(9):841–848.
   PubMedGoogle Scholar
• ALYEA E, WELLER E, SCHLOSSMAN R et al.: T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood (2001) 98(4):934–939.
   PubMed Web of Science ®Google Scholar
• PEREZ-SIMON J, CABALLERO D, MATEOS M, MIGUEL JS: Graft vs. host disease and graft vs. myeloma effect after non-myeloablative allogeneic transplantation. Leuk. Lymphoma. (2004) 45(9):1725–1729.
   Google Scholar
• KROGER N, SCHWERDTFEGER R, KIEHL M et al.: Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood (2002) 100(3):755–760.
   PubMedGoogle Scholar
• ••The effect of a planned ASCT followed byRIG allogeneic transplantation on myeloma patients.
   Google Scholar
• MALONEY DG, MOLINA AJ, SAHEBI F et al.: Allografting with non myeloabaltive conditioning following cytoreductive autograft for the treatment of patients with multiple myeloma. Blood (2003) 102(9):3447–3454.
   PubMed Web of Science ®Google Scholar
• KROGER N, SCHILLING G, EINSELE H et al: Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose- reduced stem cell transplantation. Blood (2004) 103(10:4056–4061.
   PubMedGoogle Scholar
• GILES FJ: Current therapy of refractory multiple myeloma. Stem Cells (1995) 13\(Suppl. 2):88–105.
   Google Scholar
• RAJKUMAR SV, FONSECA R, LACY MQ et al.: Autologous stem cell transplantation for relapsed and primary refractory myeloma. Bone Marrow Transplant. (1999) 23(12):1267–1272.
   PubMedGoogle Scholar
• ALEXANIAN R, DIMOPOULOS MA, HESTER J, DELASALLE K, CHAMPLIN R: Early myeloablative therapy for multiple myeloma. Blood (1994) 84(12):4278–4282.
   PubMed Web of Science ®Google Scholar
• DIMOPOULOS Mk WEBER D, KANTARJIAN H, DELASALLE KB, ALEXANIAN R: HyperCVAD for VAD-resistant multiple myeloma. Am. J. Hematol (1996) 52(2):77–81.
   PubMedGoogle Scholar
• PARAMESWARAN R, GILES C, BOOTS M et al.: CCNU (lomustine), idarubicin and dexamethasone (CIDEX): an effective oral regimen for the treatment of refractory or relapsed myeloma. Br. J. Haematol (2000) 109(3):571–575.
   PubMedGoogle Scholar
• SINGHAL S, MEHTA J, DESIKAN R et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J. Med. (1999) 341(20:1565–1571.
   PubMedGoogle Scholar
• ••The first paper to describe the effect ofthalidomide on patients with relapsed/ refractory myeloma.
   Google Scholar
• BARLOGIE B, DESIKAN R, EDDLEMON P et al.: Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood (2001) 98(2):492–494.
   PubMed Web of Science ®Google Scholar
• DIMOPOULOS MA, ZERVAS K, KOUVATSEAS G et al.: Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann. Oncol (2001) 12(7):991–995.
   PubMed Web of Science ®Google Scholar
• ANAGNOSTOPOULOS A. WEBER D, RANKIN K, DELASALLE K, ALEXANIAN R: Thalidomide and dexamethasone for resistant multiple myeloma. Br. J. Haematol (2003) 121(5):768–771.
   PubMed Web of Science ®Google Scholar
• CAVENAGH JD, OAKERVEE H: Thalidomide in multiple myeloma: current status and future prospects. Br. J. HaematoL (2003) 120(1):18–26.
   PubMedGoogle Scholar
• •A detailed review for the role of thalidomide in the management of MM.
   Google Scholar
• LEE CK, BARLOGIE B, MUNSHI N et al.: DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma. J. Clin. OncoL (2003) 21(14):2732–2739.
   PubMed Web of Science ®Google Scholar
• ••The role of a novel combination therapy(DT-PACE) in relapsed/refractory myeloma.
   Google Scholar
• DIMOPOULOS MA, HAMILOS G, ZOMAS A et al.: Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. HematoL J. (2004) 5(2):112–117.
   PubMedGoogle Scholar
• RAJKUMAR SV, HAYMAN S, GERTZ MA et al.: Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. j Clin. OncoL (2002) 20(21):4319–4323.
   PubMedGoogle Scholar
• WEBER D, RANKIN K, GAVINO M, DELASALLE K, ALEXANIAN R: Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. Clin. OncoL (2003) 21(1):16–19.
   Google Scholar
• RAJKUMAR SV, BLOOD E, VESOLE DH, SHEPARD R, GREIPP PR: Thalidomide plus dexamethasone versus dexamethasone alone in newly diagnosed multiple myeloma (E1A00): results of a Phase III trial coordinated by the Eastern Cooperative Oncology Group. Blood (2004) 104(11):63a (Abstract).
   Google Scholar
• ZERVAS K, DIMOPOULOS MA, HATZICHARISSI E et al.: Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study. Ann. OncoL (2004) 15(1):134–138.
   PubMedGoogle Scholar
• PALUMBO A, BERTOLA A, MUSTO P et al.: A prospective randomized trial of oral melphalan, prednisone, thalidomide (MPT) vs oral melphalan, prednisone (MP): an interin analysis. Blood (2004) 104(11):63a (Abstract).
   Google Scholar
• DIMOPOULOS MA, REPOUSSIS P, TERPOS E et al.: Primary treatment with pulsed melphalan, dexamethasone, thalidomide (MDT) for symptomatic patients with multiple myeloma 75 years of age. Blood (2004) 104(11):414a (Abstract).
   Google Scholar
• DIMOPOULOS MA, ELEUTHERAKIS PAPAIAKOVOU V: Adverse effects of thalidomide administration in patients with neoplastic diseases. Am. J. Med. (2004) 117(7):508–515.
   PubMed Web of Science ®Google Scholar
• ••A detailed review for the adverse effects of thalidomide in cancer patients.
   Google Scholar
• HIDESHIMA T, CHAUHAN D, HAYASHI T et al.: Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene (2003) 22(52):8386–8393.
   PubMed Web of Science ®Google Scholar
• MITSIADES N, MITSIADES CS, POULAKI V et al.: Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc. Nail. Ac. Sci. USA (2002) 99(22):14374–14379.
   PubMed Web of Science ®Google Scholar
• ••The role of proteasome inhibition inmyeloma cells.
   Google Scholar
• RICHARDSON PG, BARLOGIE B, BERENSON J et al.: A Phase 2 study of bortezomib in relapsed, refractory myeloma. N EngL J. Med. (2003) 348(20:2609–2617.
   PubMedGoogle Scholar
• ••The first study to describe the effect ofbortezomib on relapsed/refractory myeloma.
   Google Scholar
• JAGANNATH S, BARLOGIE B, BERENSON J et al.: A Phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br. J. HaematoL (2004) 127(2):165–172.
   PubMed Web of Science ®Google Scholar
• •A randomised trial comparing two doses of bortezomib 1 versus 1.3 mg/m2 in relapsed/refractory myeloma.
   Google Scholar
• RICHARDSON P, SONNEVELD P, SCHUSTER MW et al.: Bortezomib vs. dexamethasone in relapsed multiple myeloma: a Phase 3 randomized study. Proc. Am. Soc. Clin. OncoL (2004) 23:558 (Abstract).
   Google Scholar
• BERENSON J, YANG H, SWIFT R et al.: Bortezomib in combination with melphalan in the treatment of relapsed or refractory multiple myeloma: a phase I/II study. Blood (2004) 104(11):64a (Abstract).
   Google Scholar
• ORLOWSKI RZ, VOORHEES PM, GARCIA RA et al.: Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood (2005) (In press).
   Google Scholar
• JAGANNATH S, BRIAN D, WOLF JL et al.: A Phase 2 study of bortezomib as first line therapy in patients with multiple myeloma. Blood (2004) 104(11):98a-99a (Abstract).
   Google Scholar
• ALEXANIAN R, WANG LM, WEBER DM, DELASALLE KB: VTD (velcade, thalidomide, dexamethasone) as primary therapy for newly-diagnosed multiple myeloma. Blood (2004) 104(11):64a (Abstract).
   Google Scholar
• BARLOGIE B, HOLLMIG K, ZANGARI M et al.: Total therapy 3 (TT 3) for newly diagnosed myeloma, incorporating Velcade into remission induction with DT-PACE: early results regarding efficacy, PBSC mobilization and toxicities. Blood (2004) 104(11):156a (Abstract).
   Google Scholar
• TERPOS E, RAHEMTULLA A: Bisphosphonate treatment for multiple myeloma. Drugs Today (2004) 40(1):29–40.
   PubMedGoogle Scholar
• •A detailed review for the role of bisphosphonates in MM.
   Google Scholar
• DJULBEGOVIC B, WHEATLEY K, ROSS J et al.: Bisphosphonates in multiple myeloma. Cochrane Database Syst. Rev. (2002) 3:CD003188.
   Google Scholar
• BERENSON JR, HILLNER BE, KYLE RA et al.: American Society of Clin. OncoL clinical practice guidelines: the role of bisphosphonates in multiple myeloma. Clin. OncoL (2002) 20(17):3719–3736.
   PubMedGoogle Scholar
• ••The guidelines of the American Society ofClinical Oncology for the role of bisphosphonates in the management of MM.
   Google Scholar
• TERPOS E, POLITOU M, RAHEMTULLA A: New insights into the pathophysiology and management of bone disease in multiple myeloma. Br. J. HaematoL (2003) 123(5):758–769.
   PubMed Web of Science ®Google Scholar
• ••A detailed review for myeloma bone disease.
   Google Scholar
• MUSTO P, FALCONE A, SANPAOLO G et al.: Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. Leuk. Lymphoma (2003) 44(9):1545–1548.
   PubMedGoogle Scholar
• CAPARROTTI G, CATALANO L, EEO C et al.: Perspective study on pamidronate in stage I multiple myeloma. HematoL (2003) 4(61:459–460.
   Google Scholar
• RICHARDSON PG, SCHLOSSMAN RL, WELLER E et al.: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 100(9):3063–3067.
   PubMed Web of Science ®Google Scholar
• ••The first study to describe the effect of anovel IMiD, lenalidomide, on refractory/ relapsed myeloma.
   Google Scholar
• HUSSEIN MA, KARAM MA, BRAND C et al.: Doxil (D), vincristine (V), reduced frequency dexamethasone (d) and Revlimid® (DVd-R): a phase I/II trial in advanced relapsed/refractory multiple myeloma (RMM) patients. Blood (2004) 104(11):63a-64a (Abstract).
   Google Scholar
• RAJKUMAR SV, HAYMAN SR, LACY MQ et al.: Combination therapy with CC-5013 (lenalidomide; RevlimidTm) plus dexamethasone (Rev/Dex) for newly diagnosed myeloma (MM). Blood (2004) 104(11):98a (Abstract).
   Google Scholar
• SCHEY SA, FIELDS P, BARTLETT JB et al.: Phase I study of an immunomodulatory thalidomide analog CC-4047 in relapsed or refractory multiple myeloma. J. Clin. Oncol (2004) 22(10:3269-3276. The first study describing the effect of a novel IMiD, CC-4047, on refractory/ relapsed myeloma.
   Google Scholar
• ROUSSELOT P, LARGHERO J, ARNULF B et al.: A clinical and pharmacological study of arsenic trioxide in advanced multiple myeloma patients. Leukemia (2004) 18(9):1518–1521.
   PubMed Web of Science ®Google Scholar